Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20037717 | 1.00 | PDE8B (0.39) | PDE8BEPHX1ALDH1A1KDM4ETDP1 | |
| SCHEMBL13059284 | 0.94 | EPHX1 (0.38) | PDE8BEPHX1ALDH1A1KDM4ETDP1 | |
| SCHEMBL18678587 | 0.94 | EPHX1 (0.38) | PDE8BEPHX1ALDH1A1KDM4ETDP1 | |
| SCHEMBL7544684 | 0.85 | EPHX1 (0.48) | PDE8BEPHX1ALDH1A1KMT2AMEN1 | |
| SCHEMBL16589328 | 0.82 | EPHX1 (0.44) | PDE8BEPHX1ALDH1A1KDM4ETDP1 | |
| SCHEMBL8151949 | 0.79 | EPHX1 (0.41) | EPHX1ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL28741492 | 0.79 | — | — | |
| SCHEMBL12090067 | 0.78 | PDE8B (0.36) | PDE8BALDH1A1KDM4ETDP1KMT2A | |
| SCHEMBL12089502 | 0.78 | PDE8B (0.36) | PDE8BALDH1A1KDM4ETDP1KMT2A | |
| SCHEMBL8860611 | 0.78 | PDE8B (0.36) | PDE8BALDH1A1KDM4ETDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173071-A1 | TREATMENT OF MYOPIA AND OTHER OCULAR CONDITIONS USING SINGLET OXYGEN GENERATED FROM DYES ACTIVATED BY NEAR-INFRARED LIGHT | CALIFORNIA INST OF TECHN (US) | 2023-06-08 | — | — | US | disclosed |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
| US-10961253-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2020-06-25 | — | — | US | disclosed |
| WO-2020132597-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-2038286-B1 | PYRRO[1,2-B]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-7842838-B2 | Pyrro[1,2-b]pyridazinone intermediates | ANADYS PHARMACEUTICALS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090312570-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC (US) | 2009-12-17 | — | — | US | disclosed |
| US-7615651-B2 | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof | PFIZER INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7582754-B2 | For treating hepatitis C virus infections; polymerase inhibitors | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582754-B2 | For treating hepatitis C virus infections; polymerase inhibitors | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090105473-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105473-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20080167371-A1 | Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof | PFIZER INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080090814-A1 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | PDE8B 1091/4885EPHX1 3449/4885ALDH1A1 944/4885 |
| US-20080090814-A1 | PYRIDAZINONE COMPOUNDS | HAVCR2, PLPBP, CYP3A43 | PDE8B 4326/4885EPHX1 1718/4885ALDH1A1 1191/4885 |
| US-20090312570-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, CYP4B1, CYP1B1 | PDE8B 4279/4885EPHX1 2250/4885ALDH1A1 648/4885 |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | PDE8B 2436/4885EPHX1 3517/4885ALDH1A1 4539/4885 |
| US-10961253-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM4, CHRM5 | PDE8B 549/4885EPHX1 1184/4885ALDH1A1 2949/4885 |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | PDE8B 2675/4885EPHX1 3446/4885ALDH1A1 4817/4885 |
| US-20080167371-A1 | Diaryl, Dipyridinyl and Aryl-Pyridinyl Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | PDE8B 2162/4885EPHX1 2246/4885ALDH1A1 1390/4885 |
| US-20090105473-A1 | PYRRO[1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, CYP4B1, CYP1B1 | PDE8B 4279/4885EPHX1 2250/4885ALDH1A1 648/4885 |
| US-20230173071-A1 | TREATMENT OF MYOPIA AND OTHER OCULAR CONDITIONS USING SINGLET OXYGEN GENERATED FROM DYES ACTIVATED BY NEAR-INFRARED LIGHT | CRY1, MYH10, MYLK | PDE8B 2679/4885EPHX1 1234/4885ALDH1A1 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.